Neogen Corporation (NEOG) AI Stock Analysis

Neogen Corporation develops, manufactures, and markets products for food and animal safety across two primary operating segments. In Food Safety, it offers diagnostic test kits and solutions to detect foodborne pathogens, spoilage organisms, natural toxins, allergens, and drug residues, including the AccuPoint Advanced rapid sanitation test for ATP cleanliness verification. In Animal Safety, the company provides veterinary instruments, pharmaceuticals, vaccines, parasiticides, rodenticides, cleaners, disinfectants, and genomics testing services. Neogen serves agricultural, pharmaceutical, cosmetic, and veterinary sectors worldwide from its headquarters in Lansing, Michigan.

Neogen expanded revenue from $527.2M in FY2022 to $822.4M in FY2023 and $924.2M in FY2024, achieving a 5-year revenue CAGR of 13.2% from FY2021 to FY2026. Top-line sales subsequently contracted, falling 3.2% in FY2025 to $894.7M and declining 2.7% in FY2026 to $870.4M. Operating margin decreased from 11.1% in FY2022 to -2.5% in FY2026, while net income recorded -$7.9M in FY2026 following a loss of -$1.09B in FY2025. In the latest quarter ended August 31, 2026, quarterly revenue grew 6.5% year-over-year, though quarterly earnings growth fell 85.6%.

As of August 31, 2026, Neogen held $172.0M in cash and short-term investments against $774.2M in total debt, resulting in net debt of $602.2M. Total assets stood at $3.30B compared to shareholders' equity of $2.09B, reflecting a debt-to-equity ratio of 0.37 and a current ratio of 3.90. In FY2026, operating cash flow reached $83.2M and capital expenditures were $51.3M, yielding free cash flow of $31.9M. Over the past 5 years, the company's share count increased 101.7%.

Neogen trades at a forward P/E of 16.0x, which sits below the 17.3x median of its US-listed Healthcare peers. Its price-to-sales ratio of 2.9x is lower than the peer median of 4.1x, whereas its EV/EBITDA of 20.9x is higher than the peer median of 12.0x. The stock has posted a 1-year return of 99.2%, outperforming the S&P 500 return of 16.8%. However, its 5-year return of -71.2% trails the S&P 500 gain of 83.0%.

Consensus coverage on Neogen includes 1 Strong Buy, 2 Buy, and 1 Hold ratings, with no Sell recommendations. The mean price target is $14.00, representing an 18.5% upside from the last close of $11.81. For the fiscal year ending May 31, 2027, analysts project an EPS of $0.32 on revenue of $886.6M. Neogen has beaten EPS estimates in each of its last 4 quarters.

This page is an AI-written research summary of Neogen Corporation (NEOG). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NEOG income statement, NEOG balance sheet, NEOG key metrics, NEOG analyst forecast, NEOG chart. See the NEOG stock overview for the latest quote and news.